Kornimate/medical-research-clean huggingface dataset:
continuous venovenous hemofiltration versus conventional treatment for acute severe hypernatremia

Conditions: Hypernatremia; Critically Ill

Summary: the patients with severe hypernatremia who received conventional treatment are often undertreated. continuous venovenous hemofiltration (cvvh) can effectively remove solute or water from circulation system. several case reports demonstrated that cvvh could effectively decrease serum sodium concentration of the patients with severe hypernatremia. the use of cvvh for acute severe hypernatremia in critically ill patients could improve patient survival by effectively decreasing the serum sodium concentration to a normal level.

date collection: 1. demographic (gender, age, race, weight, history of drug allergy, complicating diseases, drug combination and combination therapy) 2. cvvh treatment (time, blood vessel, blood flow, replacement fluid flow, the type and dose of anticoagulant, limited to the test group) 3. vital signs (blood pressure, heart rate, respiratory frequency, body temperature) 4. severity of disease 5. general treatment (vasoactive drugs, mechanical ventilation, diuretic, steroid hormones) 6.24 hours input 7.24 hour output 8.daily sodium intake 9.adverse events were confirmed 10.laboratory date: routine blood test blood biochemical blood gas analysis blood electrolyte plasma osmotic pressure urine osmotic pressure plasma osmotic pressure urinary electrolyte excretion fraction

Eligibility criteria:
inclusion criteria: 1. age≥18 years 2. acute severe hypernatremia(increasing of serum sodium levels from normal levels to ≥160 mmol/l within 48 hours) 3. icu patients exclusion criteria: 1. hypovolemic hypernatremia fractional excretion of sodium \ 40 receiving diuretics: urea/creatinine \>40, no edema. 2. acute kidney injure network iii 3. end-stage renal disease hemodialysis or peritoneal dialysis 4. k+\>6.5mmol/l the drug is difficult to treat hyperkalemia 5. hydrogen ion concentration\<7.2 the drug is difficult to treat metabolic acidosis 6. acute pulmonary edema 7. systolic blood pressure \<90 mmhg vasoactive drugs in the treatment of systolic blood pressure less than 90 mmhg 8. the heparin or low molecular allergic patients 9. hiv positive patients 10. pregnant women or lactational pregnancy women 11. suspected tuberculosis patients

Keywords: continuous venovenous hemofiltration conventional treatment mortality acute severe hypernatremia
cefid-i (cera flow improves dvt-1)

Conditions: Blood Circulation Disorder; Deep Vein Thrombosis

Summary: the study is a single center clinical trial to evaluate the efficacy and safety of blood circulation improvement using an investigational medical device, which is a product on the market and it's name is ceragem master v6, for the risk group of deep vein thrombosis (dvt) and the ordinary person. the study compares before and after the application by one time application.

the efficacy and safety evaluation are conducted before and after (or during) the application of the test device. the investigator shall apply an investigational device once when visiting a suitable subject for one day.

Eligibility criteria:
inclusion criteria for all subjects; 1. adult men and women over 19 years of age 2. subjects who have not been diagnosed with deep vein thrombosis in the lower extremities through the following test results prior to the application of medical devices. 1. subjects diagnosed by doppler ultrasonography as having no blood clots in the femoral vein and the vena poplitea 2. d-dimer negative test result (even if the d-dimer test is positive, the subject can be selected through the additional test at the discretion of investigator.) 3. subjects who fully understand the purpose and procedure of the study and wish to participate in clinical trials with voluntary consent additional inclusion critetia for the dvt risk subjects; 1. subjects have two or more points of venous thromboembolism (hereinafter referred to as vte) clinical prediction score (two-level wells scroe) at the time of screening exclusion criteria: 1. subjects who complain of a decrease in the sensation of the lower extremities or who is unable to feel the sensation of pain 2. subjects who have inflammation or trauma on the skin that directly touches the device
transcranial magnetic stimulation for bects

Conditions: Benign Epilepsy With Centrotemporal Spikes; Language Problems; Learning Disorders

Summary: benign epilepsy with centrotemporal spikes (bects) is the most common pediatric epilepsy syndrome. affected children typically have a mild seizure disorder, but yet have moderate difficulties with language, learning and attention that impact quality of life more than the seizures. separate from the seizures, these children have very frequent abnormal activity in their brain known as interictal epileptiform discharges (ieds, or spikes), which physicians currently do not treat. these ieds arise near the motor cortex, a region in the brain that controls movement. in this study, the investigators will use a form of non-invasive brain stimulation called transcranial magnetic stimulation (tms) to determine the impact of ieds on brain regions important for language to investigate: (1) if treatment of ieds could improve language; and (2) if brain stimulation may be a treatment option for children with epilepsy. participating children will wear electroencephalogram (eeg) caps to measure brain activity. the investigators will use tms to stimulate the brain region where the ieds originate to measure how this region is connected to other brain regions. children will then receive a special form of tms called repetitive tms (rtms) that briefly reduces brain excitability. the study will measure if ieds decrease and if brain connectivity changes after rtms is applied. the investigators hypothesize that the ieds cause language problems by increasing connectivity between the motor cortex and language regions. the investigators further hypothesize that rtms will reduce the frequency of ieds and also reduce connectivity between the motor and language region


Eligibility criteria:
inclusion criteria: * a diagnosis of benign epilepsy with centrotemporal spikes (bects), sometimes called rolandic epilepsy. diagnosis will be based on a history of a focal motor seizure (affecting the face or causing hypersalivation) or a history of a seizure out of sleep and an eeg with unilateral or bilateral centrotemporal spike waves. * english-speaking exclusion criteria: * history of prematurity \< 35 weeks gestational age; * history of serious neurologic problems (i.e. history of other seizure disorder other than simple febrile seizure, head trauma with prolonged loss of consciousness, cerebrovascular accident or neuro-inflammatory disease) * focal deficits on neurologic exam * history of abnormal mri (with clear gray or white matter abnormality)

Keywords: transcranial magnetic stimulation (tms) electroencephalogram (eeg) children pediatric interictal epileptiform discharges brain connectivity
physical excercise program in children with drug-resistant epilepsy

Conditions: Epilepsy in Children

Summary: pediatric epilepsy has been described as an age related-condition, and it has a strong impact on childhood quality of life. psychological symptoms and self-esteem impairment are common facts. although there are some studies studying the benefits of physical exercise in order to improve seizure control in adults with epilepsy, we have not found studies that support it in pediatric population. few studieshave reported in childhood some benefits in terms of quality of life, self-esteem and improvement of neuropsychological symptoms. therefore, it is necessary to use a validated and applicable scale of quality of life in children with epilepsy. otherwise, findings may be difficult to reproduce


Eligibility criteria:
inclusion criteria: 1. age 5-14 years 2. diagnosis of epilepsy (must meet at least one of the following criteria): 1. at least 2 unprovoked seizures in a period of more than 24 hours 2. a seizure and probability of future seizures similar to the general risk of recurrence (60% or more) than if the patient had had 2 crises. 3. diagnosis of epileptic syndrome. 3. adequate communication skills with your family. 4. absence of significant motor limitation. 5. parents or legal guardians must have given consent to participate in the study. exclusion criteria: b) exclusion criteria: 1. failure to meet any of the aforementioned requirements. 2. failure to complete completely and/or legibly any of the instruments of evaluation. c) abandonment criteria 1. failure to deliver the submitted questionnaires in a timely manner. 2. failure to attend the scheduled appointment to complete the questionnaires control. 3. not responding to phone calls, e-mails or requests made to make a new appointment.
voices of individuals: challenges and experiences of bvftd

Conditions: Frontotemporal Dementia; Frontotemporal Degeneration; Frontotemporal Dementia, Behavioral Variant; FTD

Summary: the voice of bvftd study is a telephone interview research study about life with or at risk for behavioral variant frontotemporal dementia (bvftd). the study aims to understand how bvftd impacts individuals' day to day lives, how people think about themselves, and what challenges they face.

the voice of bvftd study is a study being conducted at the university of pennsylvania. the study was developed and initiated in collaboration with the johns hopkins bloomberg school of public health and the national human genome research institute. the goal of this study is to learn more about what it is like to live with or at high risk of developing behavioral variant frontotemporal dementia (bvftd). the study will involve telephone interviews to help learn as much as possible about living with bvftd. the hope is that this will guide future research, resource development, and clinical practice. participants will have at least two phone calls from the study team. during the initial phone call, which will take about 15 to 20 minutes, the participant will be asked some basic questions about demographics and the study details will be reviewed as part of the consent process. during another call the participant will be asked some questions to assess his or her thinking, and will complete the interview which will last about 30 to 60 minutes. there are no physical or medical procedures included in this study. the consent process, screening, interview scheduling, and the interview itself will take place over two or three phone calls, which may occur over several weeks. a person may be able to take part in this study if they are a person with bvftd, or if they have been found to have a genetic change that causes bvftd.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * speak fluent english * people with bvftd must have been diagnosed with behavioral variant frontotemporal degeneration (bvftd) * people with a known genetic risk factor for bvftd must have an identified disease-causing change in a gene that is known to cause bvftd, such as in c9orf72, mapt, grn, vcp, tardbp, chmp2b, or another gene that has been identified as causing ftd in the family * the diagnosis or genetic testing results must have been disclosed to the participant at least two months prior to study enrollment exclusion criteria: * inability to complete the informed consent comprehension process * under 18 years of age * does not speak english * received diagnosis or testing result less than two months prior to study enrollment

Keywords: ftd interview genetics persons diagnosed frontotemporal degeneration bvftd chromosome 9 open reading frame 72 (c9orf72) microtubule-associated protein tau (mapt) progranulin (grn) tar dna-binding protein (tardbp) valosin-containing protein (vcp) charged multivesicular body protein 2b (chmp2b)
efficacy of ultrasound-guided injection of 5% dextrose for meralgia paresthesia

Conditions: Meralgia Paresthetica

Summary: meralgia paresthetica (mp) is one of the most common peripheral entrapment neuropathies of the lower limbs. it is characterized by paresthesia, pain, tingling, numbness, hypersensitivity, or other abnormal skin sensations on the anterolateral aspect of the thigh. the condition results from compression of the lateral femoral cutaneous nerve (lfcn) along its course, often occurring as the nerve exits the pelvis.the injection of 5% dextrose (d5w) under ultrasound guidance is a novel treatment method for peripheral nerve entrapment. however, there is limited evidence about the efficacy of this method for patients with mp. the investigators found d5w was more safe and effective than corticosteroids for patients with mp. thus, this study aimed to evaluate the 6-month efficacy of ultrasound-guided injection of d5w for mp patients.


Eligibility criteria:
inclusion criteria: * patients aged between 18 and 80 years; * those diagnosed with mp based on clinical and physical examination, with symptoms persisting for at least 3 months; * a high-resolution ultrasound revealing lfcn compression as it exited the pelvis. exclusion criteria: * mp resulting from trauma, surgery or occupying lesions affecting the lfcn; * pregnancy; * concurrent presence of rheumatic immune diseases, hypothyroidism, or diabetes mellitus; * a known history of allergy to lidocaine or corticosteroids; * l2/3 lumbar radiculopathy; * patients who had undergone local injection or surgery for mp within 3 months

Keywords: ultrasound meralgia paresthetica d5w
the use of bone growth stimulators for osteoarthritis of the knee.

Conditions: Osteo Arthritis Knee

Summary: the hypothesis of this study is that since osteoarthritis of the knee is primarily a bone disease where the joint changes are secondary, and bone growth stimulators function to decrease intraosseous venous congestion and remodel bone, then there is a potential benefit for the treatment of osteoarthritis of the knee with bone growth stimulators.

the hypothesis of this study is based on the knowledge that osteoarthritis of the knee is primarily a bone disease, and the joint changes are secondary. bone growth stimulators function to alleviate intraosseous venous congestion through the process of bone remodeling. the working hypothesis is that alleviation of intraosseous venous congestion leads to improved delivery of nutrition to the tissue to support the health of the bone with improvement in biomechanics leading to clinical improvement. venous congestion is measured with intraosseous pressure. additional objective evidence of biomarkers of bone metabolism as well as measurements of subjective questionnaires can provide evidence of benefit.

Eligibility criteria:
inclusion criteria: 1. subjects must have diagnosis of osteoarthritis of the knee with radiographic evidence of joint space narrowing, kellgren-lawrence classification grade grade 3 or 4. 2. subjects must discontinue corticosteroids administered by any route except intranasal spray, steroid- containing ophthalmic solutions and anti-asthmatics. 3. subjects must speak english. 4. subject must be willing and able to sign an informed consent document. 5. subjects must be willing and able to comply with all study procedures for the duration of the clinical study. exclusion criteria: 1. subjects with a diagnosis of inflammatory arthritis such as rheumatoid arthritis, gout, joint infection, lyme disease, or systemic lupus erythematosus. 2. subjects with a diagnosis of secondary arthritis such as acromegaly, charcot's arthropathy, hemochromatosis, or wilson's disease. 3. subjects who have had an injury to the index knee within 6 months of starting treatment. 4. subjects must not have had arthroscopy within 8 weeks of starting treatment. 5. subjects must not have had viscosupplementation within 8 weeks of starting treatment. 6. subjects who plan to have surgery on the target knee within the study period. 7. subjects with surgical metallic hardware in the target knee. 8. subjects who are unwilling or unable to adhere to the follow up schedule and procedures. 9. subjects who are pregnant.

Keywords: osteoarthritis knee bone growth stimulators rheumatic diseases musculoskeletal diseases joint diseases arthritis
a pilot and feasibility study of a dietary intervention with low-protein meals in cancer patients receiving immunotherapies

Conditions: Medical Oncology; Integrative Oncology; Medical Nutrition Therapy

Summary: the main idea of this study is that a low protein diet may alter the environment surrounding the tumor, enhancing the body's immune response leading to greater anticancer effects of treatment. this study intends to use a low-protein diet as a tool to enhance the immune response generated by immune check point inhibitor treatments.

this is a single center, randomized, open label study to assess the feasibility of a low-protein diet intervention in cancer patients who are receiving immunotherapies. subjects will be randomized in a 1:1 ratio to either immunotherapy plus control diet arm (\~20% protein content) or immunotherapy plus intervention low-protein diet arm (10% protein content).

Eligibility criteria:
inclusion criteria: * histologically documented solid tumor malignancies which is amenable for immunotherapy treatment with immune checkpoint inhibitors (i.e. pd1, pd-l1, ctla inhibitors) as single agents or in combination. * metastatic disease as evidenced by soft tissue and/or bony metastases on baseline bone scan and/or computed tomography (ct) scan of the chest, abdomen, and pelvis * life expectancy of at least 6 months * adults ≥ 18 years of age * adequate hematologic, renal, and liver function as evidenced by the following: * white blood cell (wbc) ≥ 2,500 cells/μl * absolute neutrophil count (anc) ≥ 1,000 cells/μl * platelet count ≥ 100,000 cells/μl * hemoglobin (hgb) ≥ 9.0 g/dl * creatinine ≤ 2.0 mg/dl * total bilirubin ≤ 2 x upper limit of normal (uln) * aspartate aminotransaminase (ast, sgot) ≤ 2.5 x uln * alanine aminotransaminase (alt, sgpt) ≤ 2.5 x uln exclusion criteria: * • eastern cooperative oncology group (ecog) performance status 2 or higher * treatment with any of the following medications or interventions within 28 days of registration: * systemic corticosteroids; however, use of inhaled, intranasal, and topical steroids is acceptable. * high dose calcitriol \[1,25(oh)2vitd\] (i.e., \> 7.0 μg/week) * a requirement for systemic immunosuppressive therapy for any reason * any infection requiring parenteral antibiotic therapy or causing fever (temperature \> 100.5°f or 38.1°c) within 1 week prior to registration * a known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified ct imaging * any medical intervention or other condition which, in the opinion of the principal investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives

Keywords: oncology nutrition immunotherapy
gp2013 in the treatment of ra patients refractory to or intolerant of standard therapy

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to determine the pk/pd, efficacy and safety of gp2013 in patients with severe rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * rheumatoid arthritis as defined by the 1987 acr classification * severe active seropositive disease * inadequate response or intolerance to other dmards and anti-tnfs * treatment with methotrexate exclusion criteria: * patients with systemic manifestations of rheumatoid arthritis * female patients nursing * women of childbearing potential unless using birth control * active infection * known immunodeficiency syndrome * positive hepatitis b surface antigen or antibodies to hepatitis c * history of cancer other protocol-defined inclusion/exclusion criteria may apply
targeting caregivers to enhance health behaviors in pediatric cancer survivors

Conditions: Obesity; Cancer

Summary: this purpose of this pilot study is to investigate the feasibility of and optimal time post cancer treatment to offer caregivers a new health behavior change intervention (nourish-t), as well as assess its preliminary efficacy on specific child health behaviors. the study will also explore whether caregivers nourish-t exhibit more improvements than caregivers in euc (standard care).

approximately 40% of off-treatment pediatric cancer survivors (pcs) are overweight or obese, which increases their risk for negative long-term physical health complications. consistent with the institute of medicine's (iom) emphasis on patients transitioning from treatment to cancer survivorship and increasing long-term healthy behaviors in these survivors, we conducted a pilot rct to address the increasing overweight/obesity rates among pcs by targeting their caregivers as agents for pcs behavior change. we focused on parents' behaviors, attitudes and roles in promoting healthier eating and physical activity (pa) in pcs and adapted an evidence-informed, manualized parent intervention - nourish - found to be effective for parents of overweight and obese children and adolescents in reducing child and adolescent bmi. we adapted nourish for caregivers of 5 - 13 year old pcs (6 months -4 years off active cancer treatment). our pilot feasibility rct - nourish-t (nourishing our understanding of role modeling to improve support for healthy transitions) evaluates: 1) the preliminary feasibility efficacy of nourish-t for pcs, compared with an enhanced usual care (euc) control condition, and 2) factors to consider to improve future adaptations of the intervention. the project enrolled caregivers of pcs at two pediatric oncology clinics into the 6-week intervention (or euc) with assessments of both caregivers and pcs occurring pre- and post-6 weeks of intervention, and at a 4-month follow-up. in comparison to euc, we hypothesized that caregivers and pcs assigned to the nourish-t condition would show greater improvements in dietary intake, physical activity, and in anthropometric health indicators over time.

Eligibility criteria:
inclusion criteria: caregivers * mothers and fathers (biologic/adoptive/step parents/legal guardians) of pediatric cancer survivors * 18 years or older * fluent in english pediatric cancer survivors * diagnosis of cancer * between 5-13 years of age at study entry * off active cancer treatment for 6 months to 4 years, * reside with a participating caregiver * able to engage in pa tailored to current medical status * not taking medications that affect body weight, e.g., steroids within 6 months of enrollment * at or above the 85th bmi %ile. exclusion criteria: caregivers * are non-ambulatory * do not reside with the pcs at least 50% of the time. pediatric cancer survivor * relapse during the intervention * taken a medication known to affect body weight such as oral steroids or antipsychotic medications within 6 months of enrollment